AMYT - Chiesi Farmaceutici S.p.A. to acquire Amryt Pharma

• Chiesi Farmaceutici S.p.A. to acquire Amryt Pharma ( NASDAQ: AMYT ) for total transaction value of ~$1.25B in upfront consideration, representing a 107% premium to Amryt ADS' closing price on January 6, 2023, plus CVRs representing an additional ~ $225M of potential consideration.
• The deal expands Chiesi’s rare disease medicine portfolio.
• The deal unanimously approved and recommended by the boards of both Chiesi and Amryt and is supported by voting agreements from leading Amryt shareholders and directors .
• Per the terms, Chiesi will purchase all outstanding shares of Amryt for a purchase price per American Depositary Share of Amryt, which each represent 5 Amryt ordinary shares at $14.50 per ADS, plus contingent value rights of up to an additional $2.50 per ADS based on certain Filsuvez® milestones being achieved .
• The deal is anticipated to close by the end of the first half of 2023.

For further details see: